Drug intelligence / Profile preview

MR-107A-02

Development stage: Phase 3
Lead developer: Viatris
Modality: Small Molecules
Administration: Oral

Overview

MR-107A-02 is an orally administered nonsteroidal anti-inflammatory drug (NSAID) being developed by Viatris (previously Mylan) for the treatment of acute postoperative pain. It is classified as a new molecular entity with an undefined mechanism of action. The drug is currently in Phase III clinical trials for postoperative pain following procedures such as bunionectomy and herniorrhaphy.

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on MR-107A-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MR-107A-02.

Explore the full profile